Round Table Services LLC Raises Stake in Pfizer Inc. (PFE)

Round Table Services LLC lifted its position in Pfizer Inc. (NYSE:PFE) by 22.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,327 shares of the biopharmaceutical company’s stock after purchasing an additional 3,580 shares during the quarter. Round Table Services LLC’s holdings in Pfizer were worth $852,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Fort L.P. bought a new stake in Pfizer during the second quarter worth approximately $121,000. Smart Portfolios LLC increased its stake in Pfizer by 43.9% during the second quarter. Smart Portfolios LLC now owns 3,935 shares of the biopharmaceutical company’s stock worth $143,000 after acquiring an additional 1,200 shares during the last quarter. Selective Wealth Management bought a new stake in Pfizer during the third quarter worth approximately $155,000. Point72 Hong Kong Ltd increased its stake in Pfizer by 7,195.5% during the second quarter. Point72 Hong Kong Ltd now owns 4,815 shares of the biopharmaceutical company’s stock worth $175,000 after acquiring an additional 4,749 shares during the last quarter. Finally, Drexel Morgan & Co. bought a new stake in Pfizer during the second quarter worth approximately $200,000. 69.21% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE PFE opened at $42.53 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $252.82 billion, a P/E ratio of 16.05, a PEG ratio of 2.06 and a beta of 0.87. Pfizer Inc. has a 52-week low of $33.20 and a 52-week high of $46.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.03. The firm had revenue of $13.30 billion during the quarter, compared to analyst estimates of $13.53 billion. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. Pfizer’s quarterly revenue was up 1.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.67 earnings per share. Analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 1st. Shareholders of record on Friday, February 1st will be issued a dividend of $0.36 per share. The ex-dividend date of this dividend is Thursday, January 31st. This represents a $1.44 dividend on an annualized basis and a yield of 3.39%. This is a positive change from Pfizer’s previous quarterly dividend of $0.34. Pfizer’s dividend payout ratio is currently 51.32%.

Pfizer announced that its board has authorized a share repurchase program on Friday, December 14th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to reacquire up to 3.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Several equities research analysts have weighed in on PFE shares. Cantor Fitzgerald set a $45.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, September 26th. Barclays reissued a “neutral” rating and set a $40.00 price objective on shares of Pfizer in a research note on Wednesday, September 26th. Morningstar set a $46.00 target price on Pfizer and gave the company a “buy” rating in a research report on Thursday, September 27th. JPMorgan Chase & Co. set a $46.00 target price on Pfizer and gave the company a “buy” rating in a research report on Monday, October 1st. Finally, Independent Research set a $48.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Thursday, October 4th. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $43.67.

COPYRIGHT VIOLATION NOTICE: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2019/01/20/round-table-services-llc-raises-stake-in-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Recommended Story: What is Liquidity?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply